MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 48 Publications

11 Customer Reviews

  • Western blot of IκBζ expression in BMDMs treated with DI and stimulated with LPS for 1 h. MG132 or bafilomycin A (BafA) were added 30 min before LPS stimulation.

    Nature, 2018, 556(7702):501-504. MG-132 purchased from Selleck.

    MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

  • HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

    HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  •  

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

    JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

  • LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

    Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells M2q3N2Z2dmO2aX;uJGF{e2G7 MVOyOUDPxE1? M3PGU2ROW09? NGK4S5NKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=> MnTmNlQ3QTd2OU[=
HL-60 NV\NSo05S3m2b4TvfIlkKEG|c3H5 MnnjOFAh|ryP NU\1d4FFPDhiaB?= NF;nSW9FVVOR NYfKXYl5UUN3MEyxNEDPxE1? MWSyOFY6PzR7Nh?=
SMMC-7721 NIjxWo1EgXSxdH;4bYMhSXO|YYm= NYC5N3pNPDBizszN MXu0PEBp NEn2RW5FVVOR Mn;3TWM2OD15LkGg{txO NIH5WIYzPDZ7N{S5Oi=>
A-549 MnHyR5l1d3SxeHnjJGF{e2G7 MoDoOFAh|ryP MkC5OFghcA>? MnTBSG1UVw>? MYrJR|UxRDFyIN88US=> M1PtNVI1Pjl5NEm2
MCF-7 M4jpRmN6fG:2b4jpZ{BCe3OjeR?= M4W2b|QxKM7:TR?= NYf6WVZJPDhiaB?= M2fhfmROW09? NWDHUYZ5UUN3ME23MlMh|ryP M{T0XVI1Pjl5NEm2
SW-480 MWHDfZRwfG:6aXOgRZN{[Xl? MVq0NEDPxE1? MXq0PEBp MX\EUXNQ MYjJR|UxRTRizszN NG\aUZQzPDZ7N{S5Oi=>
NCI-H929 NXT2TGpOS3m2b4TvfIlkKEG|c3H5 MmjVNUDPxE1? MnfJO|IhcA>? MlX1SG1UVw>? M3nufWlEPTB;MD6xO{DPxE1? NV3kb4xROjR4MkWwPFg>
293T NIW5TXNEgXSxdH;4bYMhSXO|YYm= M2jXe|ExKM7:TR?= MmnnO|IhcA>? MXzEUXNQ NFXsWJBKSzVyPEKg{txO MVuyOFYzPTB6OB?=
293T NGr2R2NHfW6ldHnvckBCe3OjeR?= MWmxNEDPxE1? M2nNRlI1KGh? MUDEUXNQ MkjUUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? NFjLOJYzPDZ{NUC4PC=>
HeLa NGPaU5dMcW6jc3WgRZN{[Xl? M{nvWlExKM7:TR?= NEPvfZcyKGh? MlL5SG1UVw>? M{jFVWlv\HWlZYOgVGFTWCClbHXheoFo\SCkeTDpcohq[mm2aX7nJJBzd3OnYYPvcYUh[WO2aY\peJk> NUizVZVTOjR|MkG4N|M>
MDA-MB-231 M4LBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nrWVEh|ryP Ml7WO|IhcA>? NHPNN4xFVVOR MVLJR|UxRTBwMUig{txO MXuyOFE2OzJyNh?=
MCF-7 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxJO69VQ>? MoDkO|IhcA>? NFzyZpFFVVOR NFvN[JRKSzVyPUCuNVMh|ryP NUPH[4Z6OjRzNUOyNFY>
MCF10A NFLT[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HNTVEh|ryP MnzGO|IhcA>? NYHCe|RKTE2VTx?= NVXWTI95UUN3ME2wMlI6KM7:TR?= NF\LWlgzPDF3M{KwOi=>
HEK-293 Mn7TT4lv[XOnIFHzd4F6 MV2yJIFv\CB{MDFOwG0> MUOyJIg> M4jkUmROW09? NUnYWYxHUW6qaXLpeJMhS2iWLVygZYN1cX[rdImge4l1cCCLQ{WwJI9nKDlibl2g NXPkfpc1OjN3NEC3PVA>
Calu6 NFGzfJJHfW6ldHnvckBCe3OjeR?= MW[xNEDPxE1? NHz6R3UyQCCq MlvNSG1UVw>? Mnn3V4lodmmoaXPhcpRtgSCjY3P1cZVt[XSnczDmdoF1[XirbjDwdoVkfXK|b4K= MorPNlM2ODZ2OE[=
IFN-gamma-induced RAW264.7 Mk\FSpVv[3Srb36gRZN{[Xl? NGraR5RFVVOR MY\Jcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN NFLLNFQzOjJ5N{K3Oy=>
IPC227F MkLWR5l1d3SxeHnjJGF{e2G7 NYPreVhtOSEQvF2= MXW0PEBp NYnGbWQ1TE2VTx?= M2\5UmlEPTB;MD6wO|ch|ryP NIjiU2gzOTl{NEWyPC=>
Hepa-1c1c7 NVjIfHN4TnWwY4Tpc44hSXO|YYm= NYDUem5FOjVizszN MUW2JIg> NYrnVWxRTE2VTx?= NHnpU5lKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVt Mn\ONlA{QTJ3NES=
COS-7 NUjWWIFuS3m2b4TvfIlkKEG|c3H5 NU\uPIVPOTBizszN MYjEUXNQ NWXYUZVCUUN3MEyxNEDPxE1? MmPPNVgxQDhyOUe=
HuH-7 Mk\3R5l1d3SxeHnjJGF{e2G7 MljVNVAh|ryP MojISG1UVw>? NFntdlJKSzVyPEGwJO69VQ>? MYWxPFA5QDB7Nx?=
OCI-Ly3 NH7PbmlHfW6ldHnvckBCe3OjeR?= MkPzNVAh|ryPwrC= NIfScpk1KGh? Ml3ySG1UVw>? M4jE[2lv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP MlLBNVgxOjRzMUO=
A2780 cDDP MXTBdI9xfG:|aYOgRZN{[Xl? NIHxSogzPCCq NUTUe3A1TE2VTx?= M3nvWmlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwaHnibZRqdmdiUGTFUkBl\We{YXTheIlwdg>? NYnZXnY1OTd4OESwNVg>
LPS-stimulated RAW264.7 cells NX\ZcIlUTnWwY4Tpc44hSXO|YYm= M3LzemROW09? Mn6xTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o NIe1bYgyPzRyN{K3Oy=>
PC12 MmfxSpVv[3Srb36gRZN{[Xl? M1HiR|ExOCEQvF5CpC=> MmLuNlQhcA>? NHjBSpJFVVOR M{Px[WlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk> MkTXNVcyPTh2NUS=
PC3 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\UeVIxKM7:TR?= MYS0PEBp NIXzcFhFVVOR MX7JR|UxRTBwNjFOwG0> NHrERZgyPjZ6NkWzOy=>
LP-1 NXj5b|lFSXCxcITvd4l{KEG|c3H5 M2nzV|MxOCCwTR?= M{HGVVI1KGh? MWDEUXNQ M2ftbGlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwY4LlZZNqdmdiY3zlZZZm\CCSQWLQJIxmfmWuIHHu[EBz\WS3Y3nu[{BO[2xvMTDwdo91\WmwIHzleoVt NFnQ[2UyPTl3OEW4PS=>
ES6 NVvO[oZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K5UWlEPTB;MD6wNVMxPiEQvF2= MmntV2FPT0WU
A101D NFziNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfsU5VKSzVyPUCuNFMzPzlizszN MYHTRW5ITVJ?
OCUB-M NGjxXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMEO3N|ch|ryP NEfBSXVUSU6JRWK=
LB2518-MEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG4fllbUUN3ME2wMlA{PzZizszN Mlz0V2FPT0WU
SH-4 NUnGN4RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Uc45KSzVyPUCuNFQ{OSEQvF2= NYfqdZZqW0GQR1XS
KNS-42 NXm1botPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD1[5dPUUN3ME2wMlA1PDRzIN88US=> NVnDWpprW0GQR1XS
DSH1 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7lVG1KSzVyPUCuNFUzQDlizszN NIC3OYxUSU6JRWK=
NTERA-S-cl-D1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\aXndKSzVyPUCuNFU4PzJizszN MXTTRW5ITVJ?
D-542MG MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfDW4dKSzVyPUCuNFU6PTdizszN NF70dlBUSU6JRWK=
KS-1 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzmdmVKSzVyPUCuNFY1PThizszN MneyV2FPT0WU
BL-41 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVexeVZUUUN3ME2wMlA3QTR5IN88US=> NWHIPWZ5W0GQR1XS
LXF-289 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEewOlYh|ryP MY\TRW5ITVJ?
D-247MG M4P0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\6XotKSzVyPUCuNFczODlizszN NYHHUZBpW0GQR1XS
MMAC-SF MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\JWGpKSzVyPUCuNFczPjhizszN MUXTRW5ITVJ?
CP66-MEL NWD4elJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC2TWM2OD1yLkC3OUDPxE1? M3PrUnNCVkeHUh?=
LB771-HNC MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInsbVhKSzVyPUCuNFgxOzZizszN NVPHOWx4W0GQR1XS
no-10 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[wRmlEPTB;MD6wPFkxQSEQvF2= NIjhOYlUSU6JRWK=
A388 M{nBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;2S|lKSzVyPUCuNFkxPjVizszN NWC5[2h5W0GQR1XS
OPM-2 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBSnNFUUN3ME2wMlExPDd2IN88US=> NIG2fWhUSU6JRWK=
OVCAR-4 NHG3O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMUC5N|gh|ryP NYPHWHltW0GQR1XS
HOP-62 NFLUbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP3TWM2OD1yLkGwPVQ6KM7:TR?= MVzTRW5ITVJ?
ML-2 M2Wxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUG4NFYh|ryP MmDLV2FPT0WU
UACC-257 NH\JRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXHTWM2OD1yLkGxPVI4KM7:TR?= M1K4VHNCVkeHUh?=
NEC8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz5[ZVzUUN3ME2wMlEyQTl3IN88US=> MkHRV2FPT0WU
ONS-76 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPtV2NKSzVyPUCuNVI6OzVizszN NYr3Z4ZDW0GQR1XS
KE-37 NESxS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMUOyO|gh|ryP MlzQV2FPT0WU
HT-144 NF7GTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy1fplsUUN3ME2wMlE{QDl3IN88US=> NGruNnVUSU6JRWK=
LB2241-RCC NGHjNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHuXHJKSzVyPUCuNVQzPDdizszN MmDoV2FPT0WU
TE-5 NFHNT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G5d2lEPTB;MD6xOFI4QCEQvF2= MmryV2FPT0WU
KINGS-1 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fjPWlEPTB;MD6xOFc6KM7:TR?= M2K0THNCVkeHUh?=
NCI-H69 NUTremFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjRTWM2OD1yLkG1NVQyKM7:TR?= NYCxXot4W0GQR1XS
CAS-1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXOTZdKSzVyPUCuNVU1QDJizszN M1;WRXNCVkeHUh?=
D-263MG MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnnTWM2OD1yLkG2NFA3KM7:TR?= NFz3T4lUSU6JRWK=
A253 M{PaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMU[xNlgh|ryP NWnlcYFVW0GQR1XS
PF-382 NHvxWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD1TWM2OD1yLkG2O|A3KM7:TR?= M1jabnNCVkeHUh?=
CESS M2nsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMUewOkDPxE1? NUDTbGlqW0GQR1XS
MZ2-MEL NHK3V4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zBZmlEPTB;MD6xO|U2QSEQvF2= MXzTRW5ITVJ?
HEL NVfXPWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XqOGlEPTB;MD6xPFUyPyEQvF2= MV;TRW5ITVJ?
D-392MG M{LETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH0WWhKSzVyPUCuNVkyOTVizszN NHfQSlFUSU6JRWK=
SK-LMS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PTWmlEPTB;MD6xPVMxOyEQvF2= NGXkbmpUSU6JRWK=
GI-ME-N MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLveoxLUUN3ME2wMlE6OzB4IN88US=> M1;1S3NCVkeHUh?=
LB831-BLC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXodlNKSzVyPUCuNVk{PCEQvF2= NHL1VW1USU6JRWK=
DU-4475 NHLZfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMUm2OVgh|ryP NIra[3VUSU6JRWK=
IST-SL1 M3zqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkCwPVQh|ryP M4TKTXNCVkeHUh?=
GAK MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzFc5BvUUN3ME2wMlIxPTN2IN88US=> MX7TRW5ITVJ?
EW-1 NGjsd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS4R5JEUUN3ME2wMlIyODR5IN88US=> MmfJV2FPT0WU
LAMA-84 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMkG4OVEh|ryP MYHTRW5ITVJ?
SK-UT-1 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInJXWNKSzVyPUCuNlIxPDlizszN NFLURmhUSU6JRWK=
VA-ES-BJ M{PxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTWTWM2OD1yLkKyNlU4KM7:TR?= NYnKUohlW0GQR1XS
ACN MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf2UVdKSzVyPUCuNlI3OzhizszN MnHxV2FPT0WU
SK-PN-DW NV6wc|gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFeyPXNKSzVyPUCuNlMyQSEQvF2= NVfxPJJXW0GQR1XS
HD-MY-Z NEDiVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S5WWlEPTB;MD6yN|MxOyEQvF2= NVjXbpQxW0GQR1XS
LB373-MEL-D MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMkSxPVgh|ryP NUjP[o1UW0GQR1XS
COLO-829 M2PseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzyTWM2OD1yLkK0NlU4KM7:TR?= Mn\rV2FPT0WU
ES8 M1S1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2foPGlEPTB;MD6yOFc3OyEQvF2= MV7TRW5ITVJ?
RXF393 NIDtNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O0TWlEPTB;MD6yOVAyPSEQvF2= MknjV2FPT0WU
TK10 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrjTWM2OD1yLkK1OFM2KM7:TR?= M4X4V3NCVkeHUh?=
LOUCY NIqxeYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrZTWQ1UUN3ME2wMlI2PDV4IN88US=> M{flZXNCVkeHUh?=
MZ7-mel M1LofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf6TWM2OD1yLkK2N|c1KM7:TR?= NVjNelVzW0GQR1XS
CP67-MEL MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\rTWM2OD1yLkK2O|Mh|ryP MnTpV2FPT0WU
C2BBe1 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQVoJKSzVyPUCuNlc6ODdizszN NFjpRlRUSU6JRWK=
K052 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXkTWM2OD1yLkK4PVkh|ryP NHqweppUSU6JRWK=
MOLT-16 M4XjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMkm1NlQh|ryP MkDlV2FPT0WU
KNS-81-FD MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpZ4NKSzVyPUCuN|A{OjNizszN NI\ISJFUSU6JRWK=
CMK NXvjRpVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwM{GxNkDPxE1? NX;uPYZHW0GQR1XS
LAN-6 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[5UG9zUUN3ME2wMlMyOyEQvF2= MXnTRW5ITVJ?
KLE MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XQV2lEPTB;MD6zNVMxPiEQvF2= NXvxbpE2W0GQR1XS
NCCIT MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DYSmlEPTB;MD6zNVc5OyEQvF2= M1XxTHNCVkeHUh?=
HH NGXVeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{K4PVch|ryP NG\ZZY1USU6JRWK=
TE-8 NXLSUpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q2fGlEPTB;MD6zOFI4QSEQvF2= NGrOO4RUSU6JRWK=
GDM-1 NXTLWpI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljHTWM2OD1yLkO1NVA1KM7:TR?= MUHTRW5ITVJ?
NCI-H747 NXjyTVdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlThTWM2OD1yLkO3NVA{KM7:TR?= MYDTRW5ITVJ?
NCI-H1092 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwM{i4OFQh|ryP MXzTRW5ITVJ?
8-MG-BA NYn6XmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrTc3FKSzVyPUCuN|k5OzdizszN NXvJfFV5W0GQR1XS
NB17 NV7PZYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq2PYlKSzVyPUCuOFI6PyEQvF2= M2jpXXNCVkeHUh?=
LC4-1 M{TxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[3OoNKSzVyPUCuOFM3ODdizszN MoW3V2FPT0WU
TE-1 NGPQVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzRS|hKSzVyPUCuOFUyOTlizszN NEfmOlRUSU6JRWK=
KALS-1 NYXISWlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DucmlEPTB;MD60OlU5PCEQvF2= NELRR|JUSU6JRWK=
CCRF-CEM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qwNGlEPTB;MD60O|Y4PCEQvF2= MUnTRW5ITVJ?
OS-RC-2 M2TxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2njVmlEPTB;MD60O|k4OiEQvF2= NITuRlJUSU6JRWK=
A704 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XWdGlEPTB;MD60PFY6OiEQvF2= NGHSR3hUSU6JRWK=
BB49-HNC MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn6TWM2OD1yLkS5NFk3KM7:TR?= M4LweHNCVkeHUh?=
EVSA-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrLZ5RbUUN3ME2wMlQ6QTFzIN88US=> NUX2OmVEW0GQR1XS
Mo-T MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNUG3OlIh|ryP NED4W4NUSU6JRWK=
MONO-MAC-6 NUj4NWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jL[WlEPTB;MD61N|YyOSEQvF2= MYXTRW5ITVJ?
BB65-RCC M2Tw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGwTWM2OD1yLkW2PFEyKM7:TR?= MUfTRW5ITVJ?
NCI-H1882 NUn4cmNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwNUmwN|Yh|ryP MYrTRW5ITVJ?
TE-9 NVrXSGtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwNkGwN|Mh|ryP MVTTRW5ITVJ?
NCI-H2126 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPafFNKSzVyPUCuOlI3PjlizszN NVz3WJdpW0GQR1XS
SF268 NUjlfGFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNkW2OFEh|ryP M4\lT3NCVkeHUh?=
SW872 M{PLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwNkW3Nlkh|ryP MXLTRW5ITVJ?
LS-513 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfsTWM2OD1yLk[2O|UyKM7:TR?= MWjTRW5ITVJ?
NCI-H1355 NGrkSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LBOmlEPTB;MD62PFYyQSEQvF2= M2TQXXNCVkeHUh?=
BL-70 NHnQOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwNkmzPFgh|ryP NFXSZ3dUSU6JRWK=
NCI-SNU-5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLnc3FKSzVyPUCuOlk2PDVizszN NWDZTlFNW0GQR1XS
SNU-C2B NVLjfHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmraTWM2OD1yLkewO|M6KM7:TR?= M33LWXNCVkeHUh?=
GB-1 NUPmSVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLVWl4UUN3ME2wMlczOTJ2IN88US=> M3fDb3NCVkeHUh?=
CTB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwN{e5OVUh|ryP NW\qemRiW0GQR1XS
Becker NWnXSZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDXTWM2OD1yLke5OlIyKM7:TR?= NG\UeIpUSU6JRWK=
KM12 NGnhfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nWdGlEPTB;MD64OVQ3PiEQvF2= Mki5V2FPT0WU
ES7 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;6TWM2OD1yLki5OlUh|ryP NIDk[2lUSU6JRWK=
COLO-684 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwOUC2OVgh|ryP MkDIV2FPT0WU
HCC2998 NUnwZnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwOUO4OVQh|ryP MVPTRW5ITVJ?
TE-10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17wUmlEPTB;MD65OlQ{KM7:TR?= MWnTRW5ITVJ?
SF126 NVyyeW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTmTWM2OD1yLkm4PVcyKM7:TR?= NVvQfXhrW0GQR1XS
EKVX NIXOPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPEW4FLUUN3ME2xMlA{PDR{IN88US=> M1K5SXNCVkeHUh?=
KARPAS-45 NYjnXHdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPxTWM2OD1zLkC0NFE3KM7:TR?= MkHqV2FPT0WU
KGN NITwdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\WXXpKSzVyPUGuNFUxPDVizszN Moi4V2FPT0WU
ES1 NIrNeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMEe5NlEh|ryP M{jq[3NCVkeHUh?=
L-540 M3HzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DpSWlEPTB;MT6xNVg{QSEQvF2= NX\TSpRMW0GQR1XS
KURAMOCHI NGrJU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrOTWM2OD1zLkGyN|c1KM7:TR?= MWDTRW5ITVJ?
LU-65 M4Trbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnEZphKSzVyPUGuNVI4PTNizszN NXrG[HBvW0GQR1XS
MFH-ino MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M361R2lEPTB;MT6xO|UxOSEQvF2= NX\hOJpmW0GQR1XS
NCI-H23 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf6NlBjUUN3ME2xMlIxPDFizszN NG\Gc|hUSU6JRWK=
IA-LM M4naNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P3WWlEPTB;MT6yOFEyPiEQvF2= MojOV2FPT0WU
PSN1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxXlNKSzVyPUGuNlcxOTZizszN M1vmfXNCVkeHUh?=
NCI-H719 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwMke0NVEh|ryP MWXTRW5ITVJ?
SW684 NFLOSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjX[|NKSzVyPUGuNlg3PTlizszN NUX4e2N4W0GQR1XS
HCE-4 M1\1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fRVWlEPTB;MT6zNFIzOSEQvF2= NHTVOopUSU6JRWK=
EW-16 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:xUIh3UUN3ME2xMlMyOzR5IN88US=> NV73SWRkW0GQR1XS
NCI-H128 NIjV[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzZVG5KSzVyPUGuN|U5OTRizszN MnHOV2FPT0WU
HC-1 NHTM[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnDXlBKUUN3ME2xMlM5OTdizszN NHzJOXVUSU6JRWK=
IST-MES1 M{HnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPkS3lvUUN3ME2xMlQxOjB6IN88US=> MnXpV2FPT0WU
Raji MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X6emlEPTB;MT60NVg2KM7:TR?= MVjTRW5ITVJ?
DMS-114 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vGNGlEPTB;MT60OFU{QSEQvF2= MoDNV2FPT0WU
GI-1 NEjBd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDsRlNKSzVyPUGuOFcyOzFizszN M1OwPXNCVkeHUh?=
NCI-H2081 M3fGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwNUWxPVYh|ryP MmO4V2FPT0WU
LC-1F NFixVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrZ[nI2UUN3ME2xMlU2OTl6IN88US=> MU\TRW5ITVJ?
NCI-H2227 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;yOox{UUN3ME2xMlYyPTZzIN88US=> MV7TRW5ITVJ?
D-502MG NVTKUY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvYPVdIUUN3ME2xMlY4OjFzIN88US=> M{\keHNCVkeHUh?=
NCI-H2141 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;ve|hwUUN3ME2xMlY4OzF5IN88US=> NV73[2hQW0GQR1XS
LS-411N MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3OTWM2OD1zLk[5PFA4KM7:TR?= Mn\2V2FPT0WU
SU-DHL-1 NVvSUHJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm1TWM2OD1zLkexNlgyKM7:TR?= M3;w[nNCVkeHUh?=
BB30-HNC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXydIczUUN3ME2xMlczPjh3IN88US=> M2jsN3NCVkeHUh?=
TE-15 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwOUKzO|Mh|ryP NVywWHdxW0GQR1XS
JVM-3 M2\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT1PVBKSzVyPUGuPVM6ODRizszN NEKwOJBUSU6JRWK=
IST-SL2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlToTWM2OD1{LkCxNlUzKM7:TR?= Mom3V2FPT0WU
EW-18 NV7De5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHlc|hCUUN3ME2yMlAzOzN5IN88US=> M4ixXHNCVkeHUh?=
DJM-1 M365TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJwMEK1OVIh|ryP NViwUYtWW0GQR1XS
no-11 NEf5fZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nDb2lEPTB;Mj6wN|ExPCEQvF2= MVnTRW5ITVJ?
QIMR-WIL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPqeYZKSzVyPUKuNVY4PjJizszN NFThO|BUSU6JRWK=
MC-CAR NXX5cJE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TtPWlEPTB;Mj6yNlk2KM7:TR?= MlnIV2FPT0WU
KM-H2 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMkmwOFMh|ryP MXjTRW5ITVJ?
ECC12 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr6TWZwUUN3ME2yMlM4QTRizszN M{HhNXNCVkeHUh?=
HCE-T NEDJNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwNES4PFMh|ryP NVXEVYVQW0GQR1XS
MFM-223 NYGyTXdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfPOnZKSzVyPUKuOVA5PzFizszN NEnx[3dUSU6JRWK=
SW982 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\NTWM2OD1{LkWxOFgh|ryP NGTWR2RUSU6JRWK=
KG-1 MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jRfGlEPTB;Mj64PFc6OSEQvF2= M3L2W3NCVkeHUh?=
ES4 NE\VUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj3TWM2OD1|LkC2NVEyKM7:TR?= Mk\RV2FPT0WU
SCC-3 NWL6OVB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LUVGlEPTB;Mz6xNFg1QCEQvF2= M1T4[XNCVkeHUh?=
RH-1 M{Lmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfZcnpHUUN3ME2zMlM5PzR6IN88US=> NUHReJY3W0GQR1XS
NCI-H748 M174OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwNESyOlYh|ryP M4Hre3NCVkeHUh?=
HCC2218 NIDsb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHPTWM2OD1|LkS2PVM4KM7:TR?= MkXSV2FPT0WU
MEG-01 NVjU[Hk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnxTWM2OD1|LkW5Olgh|ryP NWqwRWxTW0GQR1XS
NB12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KzZ2lEPTB;Mz61PVg5QCEQvF2= NGnGRotUSU6JRWK=
SNB75 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH5PJVKSzVyPUOuOlAyODNizszN NX;kOVZ4W0GQR1XS
KMS-12-PE MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwNke3NlMh|ryP NVrXW|h4W0GQR1XS
SKM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5ZmZKSzVyPUOuO|E{PzZizszN MoD4V2FPT0WU
COLO-320-HSR NXXteHNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHs[2JKSzVyPUOuO|U3OzRizszN NYjTWllMW0GQR1XS
NKM-1 NEDpXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm2[mhKSzVyPUOuO|c{PzhizszN NFjGNFhUSU6JRWK=
TE-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHiTWM2OD1|Lkm0OVYyKM7:TR?= NWO5ZVdIW0GQR1XS
D-336MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRwMEGxOlYh|ryP NVv2NJdRW0GQR1XS
NCI-H1650 NUPxd4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXySVZKSzVyPUSuNVU4QTdizszN NIfnZYJUSU6JRWK=
ES3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fYRmlEPTB;ND6zNlgzPCEQvF2= M3zXdXNCVkeHUh?=
YT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGxSGdoUUN3ME20MlM2PDJ2IN88US=> MlTkV2FPT0WU
ES5 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRwNECyOVUh|ryP MmjiV2FPT0WU
LB647-SCLC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrUbnFKSzVyPUSuOVY{ODhizszN Ml;EV2FPT0WU
HAL-01 NHyzeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRwNUewN|Qh|ryP MnzMV2FPT0WU
LP-1 NUXRTXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jacmlEPTB;ND63NlM4OSEQvF2= M4nrOHNCVkeHUh?=
BC-1 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33CeWlEPTB;NT6wNFQ1PyEQvF2= NHzke4JUSU6JRWK=
EB-3 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPTZYJKSzVyPUWuNFMxPDFizszN NUjL[Yh1W0GQR1XS
GT3TKB M3vCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTVwMUe2OlIh|ryP NHHKWGdUSU6JRWK=
NCI-H209 M4PXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUezVFJkUUN3ME21MlE6OzV{IN88US=> NH\NbWNUSU6JRWK=
BT-474 NHzFZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSzXJdjUUN3ME21MlI{OTB{IN88US=> NW\G[Gx3W0GQR1XS
RKO NFzjOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDi[|ZpUUN3ME21MlI{PDJ{IN88US=> M3qzZXNCVkeHUh?=
SIMA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuwXoJnUUN3ME21MlMxPzZ3IN88US=> M3LIOHNCVkeHUh?=
RL NIDzRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nNOGlEPTB;NT6zO|U1OSEQvF2= NEjIUZlUSU6JRWK=
GCIY NWTicIRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[3fpFGUUN3ME21MlQ4OjN4IN88US=> MX3TRW5ITVJ?
Calu-6 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPvVGRKSzVyPUWuOlIzKM7:TR?= NWPLW|FCW0GQR1XS
ALL-PO Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PQWWlEPTB;NT62N|c6PSEQvF2= M1\NdXNCVkeHUh?=
ARH-77 M32zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILGblhKSzVyPUWuOlcxQDdizszN MX7TRW5ITVJ?
A4-Fuk MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DH[GlEPTB;Nj6wPFEyQCEQvF2= MV\TRW5ITVJ?
NCI-H1581 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnjXIFKSzVyPU[uNlM5PDlizszN M{Xa[XNCVkeHUh?=
HUTU-80 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNTWM2OD14LkO2PFk4KM7:TR?= MUDTRW5ITVJ?
TGW NGTHSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi2UYdKSzVyPU[uOFU2QTNizszN NIHhbotUSU6JRWK=
SK-N-FI NYezV|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjiTWM2OD14LkS1PFU1KM7:TR?= M1WxZXNCVkeHUh?=
U-266 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuO2lEPTB;Nj61NVkzPiEQvF2= MUXTRW5ITVJ?
EM-2 NW\DfGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT4W2lWUUN3ME22MlY4ODl7IN88US=> MXTTRW5ITVJ?
NMC-G1 NG\wbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwN{G4PVUh|ryP MkmzV2FPT0WU
KASUMI-1 NUTnPJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjreZA5UUN3ME22Mlg1Pzh5IN88US=> MnjDV2FPT0WU
NALM-6 M2rWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWb4lKUUN3ME22Mlg3PzV2IN88US=> M4joe3NCVkeHUh?=
OCI-AML2 NVjIWpR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rmO2lEPTB;Nz6wNFMzPiEQvF2= MUDTRW5ITVJ?
SHP-77 NVHSN5RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\wcY9oUUN3ME23MlIzPDNizszN NVXh[3ZoW0GQR1XS
NOMO-1 NHPzcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD15LkK0NlU1KM7:TR?= MV7TRW5ITVJ?
SK-N-DZ NVvmVllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXMfm1KSzVyPUeuO|ExQDlizszN NYLacmE5W0GQR1XS
LB1047-RCC NIHQWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTpb5o2UUN3ME23MlczOjNzIN88US=> NUi3UoNtW0GQR1XS
MZ1-PC NI\2[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TGdGlEPTB;Nz64OlU2QCEQvF2= M1jHXXNCVkeHUh?=
NB10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTdwOUm1OVYh|ryP NX36WoN4W0GQR1XS
RL95-2 M3TSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS5TWM2OD16LkGwPFQzKM7:TR?= M1;Fb3NCVkeHUh?=
OMC-1 NEG3OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\CTWM2OD16LkWyNVkyKM7:TR?= NFTQ[lFUSU6JRWK=
D-283MED NXjMN4RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTWTWM2OD16LkmxO|E6KM7:TR?= M3;ZfXNCVkeHUh?=
MC116 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRThwOUe5OEDPxE1? MnTrV2FPT0WU
SJSA-1 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X0fGlEPTB;OT6wPVA6OSEQvF2= Mmq0V2FPT0WU
JiyoyeP-2003 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTlwMkmzNVch|ryP NXfVcFlzW0GQR1XS
IST-MEL1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjETWM2OD17Lke0NVk5KM7:TR?= MlzpV2FPT0WU
CTV-1 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\XTWM2OD1zMD6wPVc6KM7:TR?= NWLrfGlWW0GQR1XS
NH-12 NIPrcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX2OXNKSzVyPUGwMlI1OzNizszN MUTTRW5ITVJ?
CA46 M1\SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFyLkO2NUDPxE1? MlLOV2FPT0WU
NCI-SNU-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGizTGZKSzVyPUGwMlQ6PjlizszN NHzKW5JUSU6JRWK=
SCLC-21H MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r3emlEPTB;MUCuOlU6PiEQvF2= MWjTRW5ITVJ?
EC-GI-10 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFyLkewN|Eh|ryP M33ZcnNCVkeHUh?=
SR NEP0WFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFzLkCxPFUh|ryP M17G[HNCVkeHUh?=
NCI-H1648 NHHYbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHkTJNZUUN3ME2xNU4xQTZ3IN88US=> MYTTRW5ITVJ?
TGBC1TKB NUHtdGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFzLkSxNFIh|ryP NXjqbmUzW0GQR1XS
EW-11 NVP2TotHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFzLkWxPFYh|ryP MojGV2FPT0WU
SK-MM-2 NVT4d2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;5O2lEPTB;MUGuPFA3OSEQvF2= M37rSHNCVkeHUh?=
NCI-H524 M1;Vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7vTWM2OD1zMT65PFIzKM7:TR?= NV;od5VUW0GQR1XS
NOS-1 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF{LkCzOFUh|ryP MmjrV2FPT0WU
AM-38 NEPJc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[0Z2lEPTB;MUKuOVY{OyEQvF2= NWXY[mdOW0GQR1XS
A498 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{LkewOlkh|ryP NUS4OJRJW0GQR1XS
KARPAS-422 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvPOphrUUN3ME2xNk44PDl4IN88US=> MX\TRW5ITVJ?
LU-139 NYTL[m1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHETWM2OD1zMj65NFI3KM7:TR?= NIKxNGJUSU6JRWK=
COR-L88 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2TWM2OD1zMj65N|gzKM7:TR?= NHq3eW5USU6JRWK=
K5 M{fYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT0PGEyUUN3ME2xNk46PDZ{IN88US=> M4LsZnNCVkeHUh?=
NB13 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTpboFKSzVyPUGyMlk4QDNizszN M3nIe3NCVkeHUh?=
MRK-nu-1 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvvcWhiUUN3ME2xN{4yQTVizszN MoG4V2FPT0WU
MHH-NB-11 M{LIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL4To9KSzVyPUGzMlI6ODJizszN NXm5flltW0GQR1XS
KU812 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\RfmlEPTB;MUOuOlEzPCEQvF2= MVHTRW5ITVJ?
TE-12 NFLydWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zxUmlEPTB;MUOuOlk6PCEQvF2= NIHHeVBUSU6JRWK=
NCI-N87 NH\VVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF|LkezOkDPxE1? NFTEeYVUSU6JRWK=
EB2 M1jGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPWTWM2OD1zMz64OVA2KM7:TR?= MXjTRW5ITVJ?
DB MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF|Lkm4PFUh|ryP M32wenNCVkeHUh?=
697 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHFdIJiUUN3ME2xOE41PTFzIN88US=> NHXvcohUSU6JRWK=
MSTO-211H MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF2Lke0OFgh|ryP MVHTRW5ITVJ?
JVM-2 NGn3S5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WwfmlEPTB;MUSuO|c{PSEQvF2= M4LxdHNCVkeHUh?=
COLO-824 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjXZYtKSzVyPUG0Mlc6QTRizszN NGrmNFBUSU6JRWK=
BC-3 NWHTRYdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qwSWlEPTB;MUWuN|k5KM7:TR?= MoTmV2FPT0WU
BOKU NXvTWFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPxXIg5UUN3ME2xOU46PjB6IN88US=> M1jiSXNCVkeHUh?=
GOTO MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzyWJFKSzVyPUG2Mlk3OTdizszN MXrTRW5ITVJ?
HCC2157 NF;mXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjseYtkUUN3ME2xO{41PzV3IN88US=> MVLTRW5ITVJ?
LS-1034 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF5Lk[4NVgh|ryP MV7TRW5ITVJ?
CAL-148 NYT5fpdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3KO2JKSzVyPUG3Mlk4QTZizszN NW[wR3E2W0GQR1XS
MOLT-4 M3;rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTxOWRkUUN3ME2xPE45OjB6IN88US=> M3mwPXNCVkeHUh?=
Daudi MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC0O3FKSzVyPUG4MlkzOzFizszN M2XY[3NCVkeHUh?=
J-RT3-T3-5 M2jSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxT|ZKUUN3ME2xPU41ODZ4IN88US=> M2G4O3NCVkeHUh?=
KMOE-2 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK5TWM2OD1zOT62OFgzKM7:TR?= NVXMfFdSW0GQR1XS
HL-60 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\TTWM2OD1{MD6xPVY2KM7:TR?= MmGzV2FPT0WU
P31-FUJ MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLLZldKSzVyPUKwMlQ4PTNizszN NWPaPJZCW0GQR1XS
IM-9 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zS[2lEPTB;MkCuOlIzPCEQvF2= MYfTRW5ITVJ?
HDLM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nCOGlEPTB;MkCuPFgzOSEQvF2= MULTRW5ITVJ?
NCI-H1304 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPTfWFKSzVyPUKxMlA{OTFizszN M3vVV3NCVkeHUh?=
NCI-H345 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJzLkC2OFMh|ryP NVrVdItNW0GQR1XS
RPMI-6666 NV[4RlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\z[HlXUUN3ME2yNU4{PjB{IN88US=> NEnwVWZUSU6JRWK=
GR-ST NYHqdYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ETWM2OD1{MT60NVch|ryP NGnnU4lUSU6JRWK=
CHP-126 NITobGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXXTWM2OD1{MT62NVgyKM7:TR?= MVrTRW5ITVJ?
EHEB Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7jNIpLUUN3ME2yNU43PzNzIN88US=> NX65c4tFW0GQR1XS
CPC-N MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ2LkCyNFEh|ryP MULTRW5ITVJ?
NB1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzWepZOUUN3ME2yOE43QTN7IN88US=> NGXuSXdUSU6JRWK=
LS-123 NVK3PHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLjWHR4UUN3ME2yOE46ODF{IN88US=> MmfxV2FPT0WU
ST486 M1H4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfyTlVKSzVyPUK1MlEyOTNizszN MXzTRW5ITVJ?
NCI-H1963 NHPOT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojETWM2OD1{Nj6wOlI{KM7:TR?= MmmzV2FPT0WU
U-87-MG NHH6UJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPLZZJYUUN3ME2yOk44PjR2IN88US=> M3PoeXNCVkeHUh?=
COR-L279 NGTpW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ4Lke5NlIh|ryP M3\JVnNCVkeHUh?=
LU-165 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXUenp6UUN3ME2yPE4xQDZzIN88US=> M2ntd3NCVkeHUh?=
COLO-800 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmwdHNKSzVyPUK4MlI6PTZizszN NFTYcWNUSU6JRWK=
ETK-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzuTWM2OD1{OD6zOFQ3KM7:TR?= NUfpNYN6W0GQR1XS
LNCaP-Clone-FGC M13xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O5dWlEPTB;MkmuPVI5OSEQvF2= NXLvTmg1W0GQR1XS
SIG-M5 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTNyLke5OVIh|ryP NGHqfWtUSU6JRWK=
NB6 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\TUWlEPTB;M{CuPVUxOyEQvF2= MU\TRW5ITVJ?
NCI-H2107 NWDVNZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ZTWM2OD1|MT6yN|M5KM7:TR?= NVPvOppxW0GQR1XS
SNU-C1 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNzLkOxNlYh|ryP MYrTRW5ITVJ?
JAR NV7xPXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXxdlRwUUN3ME2zNU4{Pzl7IN88US=> NHPFRndUSU6JRWK=
L-363 NH\BOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN{LkKxOFQh|ryP NX:1RY41W0GQR1XS
EW-24 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTN{LkO0O|Qh|ryP M2j5SHNCVkeHUh?=
NB69 M1SxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojKTWM2OD1|Mz62OFU1KM7:TR?= MoK4V2FPT0WU
EW-13 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zCZmlEPTB;M{OuPFk3QSEQvF2= NWPMZZVOW0GQR1XS
Ramos-2G6-4C10 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XVpdMUUN3ME2zOE4zQTl|IN88US=> M2DseHNCVkeHUh?=
TE-11 NE\zfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq0[25KSzVyPUO0MlQ5OjJizszN MnfnV2FPT0WU
L-428 M36wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\lOmlEPTB;M{SuO|U{PiEQvF2= M2DmcnNCVkeHUh?=
KP-N-YN Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe5RnJZUUN3ME2zOE46ODV5IN88US=> MorxV2FPT0WU
CGTH-W-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnDTFNKSzVyPUO2MlkxPDhizszN NVHaUmx6W0GQR1XS
K-562 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv2ZmVmUUN3ME2zO{4xQDZ2IN88US=> NXXCNZplW0GQR1XS
NCI-H1299 NU\4eol4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TremlEPTB;M{iuNVYxOyEQvF2= NF3neHNUSU6JRWK=
RCC10RGB NX\4cGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXGdGtoUUN3ME2zPE4zODh|IN88US=> NFvtWYtUSU6JRWK=
NCI-SNU-16 NWLzPJliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGT5RrUUN3ME2zPE42PjV|IN88US=> M1f1eHNCVkeHUh?=
LC-2-ad MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTN7LkSzN|ch|ryP NWr3O5B1W0GQR1XS
MHH-PREB-1 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nBZmlEPTB;M{muO|M5QCEQvF2= MYLTRW5ITVJ?
NCI-H64 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3KS4Z7UUN3ME20NE4xQTR6IN88US=> MX;TRW5ITVJ?
LB996-RCC M{PTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRyLki3NVYh|ryP MX;TRW5ITVJ?
DEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjhUpBKSzVyPUSxMlQ1ODVizszN M1mzU3NCVkeHUh?=
MLMA NFHEZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRzLke1PVUh|ryP NH:xdVhUSU6JRWK=
SBC-1 NHq3bG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHvfo5KSzVyPUSyMlE5ODZizszN MVLTRW5ITVJ?
MPP-89 M4W3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR{LkW4O|Uh|ryP M1TRbHNCVkeHUh?=
MV-4-11 NGLvbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;pcFZKSzVyPUSyMlkxPjdizszN MlzlV2FPT0WU
EoL-1- M2WyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXiTWM2OD12ND6xOVY5KM7:TR?= MXHTRW5ITVJ?
CW-2 M3K3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOxbIRKSzVyPUS0Mlg{PDJizszN NInX[VZUSU6JRWK=
HT M3TPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnvUGpKSzVyPUS1MlcxODdizszN MXTTRW5ITVJ?
SW954 NHO3eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR5LkSxNlgh|ryP MXnTRW5ITVJ?
A3-KAW MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrre5NWUUN3ME20PU45ODZzIN88US=> MWTTRW5ITVJ?
TC-YIK M{ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjCUWVKSzVyPUWwMlA{PjNizszN NWPYcGxMW0GQR1XS
SW962 NVrNO4p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS5dWtKSzVyPUW0Mlg{PTdizszN NWPuUoR6W0GQR1XS
KP-N-RT-BM-1 NXTSO3pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PCbGlEPTB;NU[uOlY{QCEQvF2= Ml\nV2FPT0WU
NCI-H1395 NFHGZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTV6LkixO|Ih|ryP NHLMWJJUSU6JRWK=
RPMI-8402 M3rvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTV6Lkm1NlYh|ryP MXvTRW5ITVJ?
SCH Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;U[GlEPTB;NkCuPVY{QCEQvF2= NHnkZ|RUSU6JRWK=
NCI-H2196 M4H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTZzLkKzNUDPxE1? NWjGWVU5W0GQR1XS
LOXIMVI NYnRcZN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHaTWM2OD14MT64NlY3KM7:TR?= MVrTRW5ITVJ?
TGBC24TKB M4HFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDoTWM2OD14Mj6xOFkyKM7:TR?= M4nmUXNCVkeHUh?=
SK-MEL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHH[FRKSzVyPU[zMlk5QTJizszN MVvTRW5ITVJ?
U-698-M NFG1cmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rZcmlEPTB;NkiuOVY5PyEQvF2= MUDTRW5ITVJ?
NCI-H1522 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZ7LkCwOFch|ryP NEDaZmtUSU6JRWK=
UACC-812 NHG5RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPwXGNiUUN3ME22PU42OjB7IN88US=> M17sfXNCVkeHUh?=
MHH-CALL-2 M3LHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0elZKSzVyPUewMlA3KM7:TR?= M3vGS3NCVkeHUh?=
NB5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzzTWM2OD15MD6zOFY5KM7:TR?= NEWz[IFUSU6JRWK=
KARPAS-299 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjNepFKSzVyPUewMlQ1PDdizszN M1\6S3NCVkeHUh?=
NCI-H1694 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnL[nVzUUN3ME23NU4xOzJizszN Mon4V2FPT0WU
NCI-H82 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPC[XZMUUN3ME23NU46PTB5IN88US=> NXPOVGpCW0GQR1XS
SCC-15 NHixc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;MVGRKSzVyPUeyMlM1KM7:TR?= NIrnb5dUSU6JRWK=
NCI-H1436 M{TFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\GTWM2OD15Mj63OFU3KM7:TR?= Mm\mV2FPT0WU
ATN-1 NFu5[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTd2LkWwOUDPxE1? NEW0ZmVUSU6JRWK=
RPMI-8866 NFrP[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTJTWM2OD15ND63OVA6KM7:TR?= NUniOmVoW0GQR1XS
HCC1599 M3r2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HmPGlEPTB;N{SuPFc{OiEQvF2= MUHTRW5ITVJ?
NCI-H1155 NFvGZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLwO4pWUUN3ME23OE46OzZ5IN88US=> M{m2WXNCVkeHUh?=
DOHH-2 NUXDVG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjYOYhjUUN3ME23OE46PTF2IN88US=> MXTTRW5ITVJ?
SK-NEP-1 NUXtSGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTd3LkC3OVQh|ryP M1XufHNCVkeHUh?=
HCC1187 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTjfHdKSzVyPUe3MlYyOjJizszN NEjQU3lUSU6JRWK=
NCI-H322M M3L2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD15OD6zO|A6KM7:TR?= NYL0U21yW0GQR1XS
NCI-H526 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfnV3FsUUN3ME23PE42QDd5IN88US=> M33kS3NCVkeHUh?=
NCI-H2171 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn32TWM2OD15OT60NVM3KM7:TR?= MmXaV2FPT0WU
COLO-668 NFjYV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfhTWM2OD16MT61PFg1KM7:TR?= NX\rcVVsW0GQR1XS
RS4-11 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQeoxZUUN3ME24Nk4zPTB3IN88US=> NGrUfVFUSU6JRWK=
NCI-H716 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\xTWM2OD16Mj65NFc2KM7:TR?= NH;I[2pUSU6JRWK=
LU-134-A M2XtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7mbZJKSzVyPUizMlE{PTFizszN NH3VRllUSU6JRWK=
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi5c|dOUUN3ME24OE4zOTB5IN88US=> NF\PSGZUSU6JRWK=
KY821 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTlzLk[1OVEh|ryP M{jmWnNCVkeHUh?=
ECC4 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q4VGlEPTB;OUOuPFI3QSEQvF2= MY\TRW5ITVJ?
EW-3 M3XSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlriTWM2OD17ND65NFgyKM7:TR?= M4L3NXNCVkeHUh?=
NB7 NVHGVZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjoVHhKSzVyPUm1Mlc4QDZizszN M4PD[XNCVkeHUh?=
NCI-H720 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;5WFJkUUN3ME25PE41ODZzIN88US=> M1\lNXNCVkeHUh?=
NCI-H446 NXzBNVFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrjfpZKSzVyPUm5Mlc2QDhizszN M3Hmc3NCVkeHUh?=
NCI-H889 NYPVV4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T5b2lEPTB;MUC0MlI1OiEQvF2= MUHTRW5ITVJ?
EW-22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOwTWM2OD1zME[uNVkh|ryP NGjvOnJUSU6JRWK=
BV-173 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjiXVhKSzVyPUGwPE44OjhizszN MknmV2FPT0WU
WSU-NHL Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTsNlVYUUN3ME2xNFkvPjdzIN88US=> NE\EfFhUSU6JRWK=
MN-60 M4LKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFyOT62PUDPxE1? NFTycIhUSU6JRWK=
DG-75 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTaTWM2OD1zMUOuN|UzKM7:TR?= NWXkNGM2W0GQR1XS
DMS-79 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjKOlNoUUN3ME2xNVcvOzh{IN88US=> NUXKVXNDW0GQR1XS
SK-MEL-1 M4XSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfZ[plvUUN3ME2xNVgvODB7IN88US=> MkK5V2FPT0WU
DMS-153 NWq2eoJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L3TWlEPTB;MUKxMlc1PSEQvF2= NEDpNpBUSU6JRWK=
NCI-H510A MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nzdWlEPTB;MUK3MlMzKM7:TR?= MoLnV2FPT0WU
BE-13 NHfnTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\KR2lEPTB;MUO0MlA1PCEQvF2= MluwV2FPT0WU
KP-N-YS NYnHOJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SwcmlEPTB;MUO5Mlc{PiEQvF2= MkjjV2FPT0WU
SUP-T1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfSW|hKSzVyPUG0N{44ODhizszN NHrD[XRUSU6JRWK=
EW-12 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LrRmlEPTB;MUS0MlY6QSEQvF2= MoDxV2FPT0WU
NB14 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyTWM2OD1zNEeuNFgzKM7:TR?= MlL1V2FPT0WU
MDA-MB-134-VI NIHiSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF2OD6yOlgh|ryP Mk\hV2FPT0WU
NCI-H1770 M1TUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\4bWlEPTB;MUW2MlI4QSEQvF2= MVPTRW5ITVJ?
TUR NYPzfWNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLjTWM2OD1zNkeuPFch|ryP M2j5V3NCVkeHUh?=
NCI-H1417 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\OTWM2OD1zOECuN|MyKM7:TR?= NYjpPFh{W0GQR1XS
IMR-5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF6MT61O|Eh|ryP MXXTRW5ITVJ?
NCI-H226 M{LU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF6OD64OlYh|ryP NYLLZ|JCW0GQR1XS
NCI-H187 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13pWGlEPTB;MUmwMlA3PCEQvF2= M1vvZ3NCVkeHUh?=
SF539 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjzcWNHUUN3ME2xPVIvPzJ6IN88US=> NIXZdmFUSU6JRWK=
TALL-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDtbVJKSzVyPUG5PE4{ODRizszN MmPTV2FPT0WU
TE-441-T M1vZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfSW2xqUUN3ME2xPVkvPzN7IN88US=> MUXTRW5ITVJ?
REH MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzqSIpKSzVyPUKzOk43OjZizszN NIrEWVZUSU6JRWK=
MS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3adWJ7UUN3ME2yN|kvOTJzIN88US=> MX3TRW5ITVJ?
THP-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP0[oRiUUN3ME2yOlQvPzN6IN88US=> MX3TRW5ITVJ?
NCI-H1838 NVrYXWdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ5MT60OVYh|ryP NUDyc25yW0GQR1XS
P30-OHK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrWTWM2OD1{OEOuPFQ4KM7:TR?= MnTCV2FPT0WU
C8166 M{SyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPCS4JNUUN3ME2zOFUvOzN6IN88US=> M4jObHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID